A novel capsular tension ring as local sustained-release carrier for preventing posterior capsule opacification
A novel capsular tension ring as local sustained-release carrier for preventing posterior capsule opacification
复制标题
DOI：
10.1016/j.biomaterials.2016.02.038
复制
发表时间：
2016-05-01
期刊：
影响因子：
14
通讯作者：
Zhao, Chunshun
中科院分区：
文献类型：
--
作者：
Lei, Ming;Peng, Zihang;Zhao, Chunshun
药物预防后囊混浊的最重要和最具挑战性的目标之一是在不影响患者视力的情况下长期保持囊袋中的有效药物浓度。本文采用甲基丙烯酸羟乙酯（HEMA）和甲基丙烯酸甲酯（MMA）两步法制备了一种新型的复合材料，并将其应用于囊袋张力环（LIR），作为一种能够长期释放多西他赛（DTX）的植入物。复合材料的药物释放速率可通过调节EGDMA含量、HEMA/MMA比例以及PMMA多孔骨架结构来控制。CTR在体外可持续释放DTX长达6周，并在42天后保持DTX在有效浓度。多西他赛囊袋张力环（DTXCTR）在体内对透镜上皮细胞有较强的抑制作用，对正常组织无明显损伤。这些结果表明，药物缓释CTR可以提供一个有前途的应用在后囊膜混浊的预防。(C)2016爱思唯尔有限公司版权所有。
One of the most important and challenging goals in pharmaceutical prevention for posterior capsule opacification is to preserve an effective drug concentration in capsular bag for a long period without affecting the patients' vision. Here, a novel kind of composite, which was prepared by 2-hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA) via a two-step process, was applied for capsular tension ring (LIR) as an implant that could deliver docetaxel (DTX) over a long period of time. The drug release rate of the composite could be controlled by the ethyleneglycol dimethacrylate (EGDMA) content and the ratio of HEMA/MMA as well as the structure of porous PMMA framework. The CTR could continuously release DTX for up to 6 weeks in vitro and maintain DTX in effective concentration in the aqueous humor after 42 days. Docetaxel-load capsular tension ring (DTX CTR) presented strong inhibition on the lens epithelial cells in-vivo without obvious damage to normal tissues. These results indicate that the drug sustained-release CTR can provide a promising application in posterior capsule opacification prevention. (C) 2016 Elsevier Ltd. All rights reserved.